Long-term protection of hepatitis B vaccination among Egyptian children

Background: Hepatitis B Vaccination is the most effective way to prevent transmission of hepatitis B virus (HBV). Objective: to detect the long-term immunogenicity of the vaccine in Egyptian children after five and ten years of vaccination. Methods: Two hundreds healthy children were recruited. They were divided into two groups according to their age. Group A included 100 child, around 6 years old, vaccinated 5 years ago. Group 'B' included 100 child, around 11 years old, vaccinated 10 years ago. Hepatitis B surface antibody (HBsAb) titre was tested, booster dose of the vaccine was given to children whose HBsAb was < 10 mIU/ml, then one and half month later, they were retested for HBsAb to evaluate the response. Results: Both groups had a wide range of HBsAb (2-1000 mlU/ml), and there was a significant difference in the level of the two groups. Our data proves the decline of antibody titre with time. In group A, 19 children needed a booster dose, 14 of them were vaccinated, and 10 were retested after one and half month. The results showed that 9 (90%) responded by increased level of HBsAb, with six (66.6%) showing an adequate response. In group B, 52 children had antibody titre < 10, 48 of them were vaccinated and 34 were retested one and half months later. Two out of the 34 did not respond and 32 (94.2%) responded by an increase in the antibody titre. Of those who responded, 19 had adequate response (HBsAb >= 100) and 13 had hypo-response (HBsAb = 10 -100). Eighty percent (80%) of boys versus 51.7% of girls responded adequately. Conclusion: Hepatitis B vaccine is an effective and successful way for preventing HBV infection. No need for booster dose at least for 5 years after vaccination.